Arber DA, et al. The 2016 revision to the WHO classification of myeloid neoplasms and acute leukemia. Blood 2016;127(20):2391-405.
Malcovati L, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011;118(24):6239-46.
Greenberg PL, et al. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. J Natl Compr Canc Netw 2022;20(2):106-117.